COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Pinja Jalkanen, Pekka Kolehmainen, Hanni K. Häkkinen, Moona Huttunen, Paula A. Tähtinen, Rickard Lundberg, Sari Maljannen, Arttu Reinholm, Sisko Tauriainen, Sari H. Pakkanen, Iris Levonen, Arttu Nousiainen, Taru Miller, Hanna Välimaa, Lauri Ivaska, Arja Pasternack, Rauno Naves, Olli Ritvos, Pamela Österlund, Suvi Kuivanen, Teemu Smura, Jussi Hepojoki, Olli Vapalahti, Johanna Lempainen, Laura Kakkola, Anu Kantele & Ilkka Julkunen

As SARS-CoV-2 has been circulating for over a year, dozens of vaccine candidates are under development or in clinical use. The BNT162b2 mRNA COVID-19 vaccine induces spike protein-specific neutralizing antibodies associated with protective immunity. The emergence of the B.1.1.7 and B.1.351 variants has raised concerns of reduced vaccine efficacy and increased re-infection rates. Here we show, that after the second dose, the sera of BNT162b2-vaccinated health care workers (n = 180) effectively neutralize the SARS-CoV-2 variant with the D614G substitution and the B.1.1.7 variant, whereas the neutralization of the B.1.351 variant is five-fold reduced. Despite the reduction, 92% of the seronegative vaccinees have a neutralization titre of >20 for the B.1.351 variant indicating some protection. The vaccinees’ neutralization titres exceeded those of recovered non-hospitalized COVID-19 patients. Our work provides evidence that the second dose of the BNT162b2 vaccine induces cross-neutralization of at least some of the circulating SARS-CoV-2 variants.
The emergence and spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic with over 3.8 million deaths and rapid development of multiple vaccine candidates. SARS-CoV-2 infection elicits antibodies against spike protein (S) and nucleoprotein (N), of which, on the basis of virus challenge studies in animals, the spike protein-specific antibodies are neutralizing and associated with protective immunity. Although the persistence of vaccine-induced antibodies is still not known, infection-induced neutralizing antibodies have remained detectable for at least six months after symptom onset.

Currently, European Medicines Agency (EMA) has authorized four vaccines to be used in European Union: two mRNA vaccines (BNT162b2/Comirnaty by Pfizer-BioNTech and mRNA-1273 by Moderna) and two adenoviral vector-based vaccines (ChAdOx1-S by AstraZeneca-Oxford and COVID-19 Vaccine Janssen by Janssen Biologics B.V. and Janssen Pharmaceuticals NV). All four vaccines aim to generate spike protein-specific antibodies and all have been shown to induce anti-S IgG antibodies with neutralizing activity against the first pandemic SARS-CoV-2 Wuhan Hu-1 variant and the currently circulating D614G variants. The recent emergence of SARS-CoV-2 variants of concern, such as B.1.1.7 first identified in the United Kingdom and B.1.351 first identified in South Africa, has raised concerns about increased virus transmissibility and reduced vaccine efficacy. These two variants of concern are defined by eight to ten amino acid changes or deletions in the spike protein to which vaccine-induced antibodies are targeted. Both of these variants are now transmitted in several countries.

Initial studies reported that antibodies produced in response to vaccination and natural infection neutralize the B.1.1.7 variant, whereas neutralization of the B.1.351 is reduced by 8–13-fold. However, it is still unclear whether the B.1.351 variant can escape from humoral and cell-mediated immunity.

Here, we characterize the BNT162b2 vaccine-induced antibody responses among a sequential serum sample cohort of 180 Finnish healthcare workers who, belonging to the group vaccinated first in Finland, received two doses of COVID-19 vaccine with three weeks interval. SARS-CoV-2 S1-specific IgG, IgA, and IgM antibody responses and neutralization titres for three SARS-CoV-2 variants were determined. We show that two-dose immunization yields high levels of anti-S1 IgG antibodies in 100% of vaccinees. The second vaccine dose induces antibodies for efficient neutralization of D614G and B.1.1.7. variants, whereas the neutralization titres for B.1.351 are lower.

**Characterization of SARS-CoV-2 isolates.** To analyze the neutralization capacity of the vaccinees’ sera, we isolated for micro-neutralization tests four virus variants circulating in Finland: D614G variants FIN-25 (spring 2020) representing B.1.1.7 lineage and SR121 (autumn 2020) representing B.1.463 lineage, a variant of concern 85HEL representing B.1.1.7 lineage and a variant of concern HEL12-102 representing B.1.351 lineage. FIN-25 isolate was passaged first in VeroE6 cells followed by passaging in VeroE6 cells expressing transmembrane protease serine 2 (VeroE6-TMPRSS2-H10). Other three isolates were passaged in VeroE6-TMPRSS2-H10 cells to avoid the generation of mutations in the vicinity of the furin cleavage site. The isolates were sequenced to compare the mutations in SR121, 85HEL (B.1.1.7), and HEL12-102 (B.1.351) variants to FIN-25 that represented the circulating strains in Finland until the emergence of variants of concern. Sequence analysis of SARS-CoV-2
isolates revealed 3 amino acid changes in the spike protein of FIN-25, 4 in SR121, 10 in 85HEL (B.1.1.7), and 9 in HEL12-102 (B.1.351) variants compared to the original Wuhan Hu1 strain (Fig. 2A). The sequence of FIN-25 that was passaged initially in VeroE6 cells had closest to the furin cleavage site an deletion of amino acids 674–678 in 45% and R682W mutation at the furin cleavage site in 41% of the virus population, indicating some heterogeneity of the FIN-25 virus stock, which did, however, not affect the growth properties of the virus. Sequences of the three other isolates passaged in VeroE6-TMPRSS2-H10 cells only had either aforementioned deletion in the minority of the virus population (8% of SR121) or a completely intact furin cleavage site. Otherwise, all spike protein sequences obtained from the virus propagations were identical to the sequences obtained from the respective original patient sample, all also contained the D614G substitution linked to increased fitness and transmissibility24,25.

**Fig. 1 Antibody responses against SARS-CoV-2 S1 and N proteins in BNT162b2 vaccinated health care workers and non-hospitalized recovered COVID-19 patients.** A Anti-S1 and B anti-N IgG, IgA, IgM, and total Ig antibody levels were measured with EIA. Serum samples from BNT162b2 vaccinated initially seronegative participants (n = 169) were collected before vaccination (0d), and three (3wk) and six (6wk) weeks after the first dose of the vaccine. All vaccinees received the second dose of the vaccine three weeks after the first dose. Convalescent phase patient samples (Conv, n = 50) were collected 14 days–6 weeks after the positive RT-qPCR test result. Data are represented as geometric means and geometric standard deviations (SD). Cut-off values are indicated with dashed lines.

|                  | 0d       | 3wk      | 6wk      | Convalescent |
|------------------|----------|----------|----------|--------------|
| **EIA**          |          |          |          |              |
| Anti-S1 IgG      | 1 (1.4–1.7) | 0% (0/169) | 47 (43–52) | 107 (105–108) |
| Anti-S1 tot Ig   | 2 (1.7–2.2) | 4% (6/169) | 37 (33–41) | 86 (85–88) |
| Anti-N IgG       | 2 (1.9–2.4) | 4% (6/169) | 7% (1.9–2.5) | 2 (1.8–2.4) |
| **MNT**          |          |          |          |              |
| FIN-25           | 10 (10–10) | 0% (0/169) | 24 (21–28) | 234 (210–261) |
| SR121            | 10 (10–10) | 0% (0/84) | 32 (27–37) | 275 (234–323) |
| 85HEL            | 10 (10–10) | 0% (0/169) | 24 (21–28) | 240 (214–269) |
| HEL12-102        | 10 (10–10) | 0% (11–13) | 12 (15% | 48 (25–167) |

HCW serum samples (n = 169) were collected before vaccination (0d), and three (3wk) and six (6wk; three weeks after the second vaccine dose) weeks after the first vaccine dose. Geometric means (GM), 95% confidence intervals (CI) and the number of positive samples for anti-S1 IgG and total Ig, and anti-N IgG antibodies and neutralizing antibodies is indicated. In microneutralization test (MNT) neutralization titre 20 or higher was considered positive and for calculation of geometric means a value of 10 was given for values of <20.
The availability of the 3-dimensional structure of the SARS-CoV-2 spike protein enabled the positioning of the amino acid changes into the structure of the trimeric spike protein (Fig. 2B). Substitutions found in FIN-25 and SR121 spike proteins localize in the stem regions of the trimeric spike protein. The substitutions found in the spike proteins of B.1.1.7 and B.1.351 variants located both to the stem region and on the surface of the trimeric spike protein close to the receptor-binding domain (RBD). The three B.1.351 variant substitutions E484K, K417N, and N501Y are in the groove of the RBD–ACE2 interaction domain. In addition, both the B.1.1.7 and B.1.351 variants had three amino acid deletions in the far edges of the 3-dimensional domain. In addition, both the B.1.1.7 and B.1.351 variants had three amino acid deletions in the far edges of the 3-dimensional structure (Fig. 2B). Figure 2C shows combined amino acid changes found in the isolates used in this study indicating the accumulation of substitutions on multiple localizations on the trimeric structure of the spike protein. The amino acid changes in the spike protein, especially the aforementioned E484K, K417N, and N501Y have recently been reported to affect the neutralizing efficacy of the antibodies.

Neutralizing antibody titres against SARS-CoV-2 variants. To measure the neutralizing potential of the vaccinees’ sera against all four SARS-CoV-2 isolates, neutralizing antibody titres elicited by the BNT162b2 vaccine were analyzed with microneutralization test (MNT). The neutralizing titres with two D614G isolates FIN-25 and SR121 were almost identical both 3 weeks (p = 0.02) and 6 weeks after the first dose (p = 0.11) (Fig. 3A), indicating that the mutations in FIN-25 spike protein due to initial propagation in VeroE6 cells did not affect the neutralizing titres.

Before vaccination (0 day sampling) those 11/180 with a likely previous SARS-CoV-2 infection based on EIA results, showed increased geometric mean titres (GMT) of 35, 31, and 16 against FIN-25, 85HEL (B.1.1.7), and HEL-12-102 (B.1.351) virus isolate, respectively. Following the first and the second vaccination, the GMTs further increased to 435 and 682, to 320 and 640, and to 101 and 132, respectively (Supplementary Fig. 1B). These results with this small group indicate that even one dose of the BNT162b2 vaccine induces high MNT titres in those individuals who had suffered a previous COVID-19 infection.

None of the vaccinees without a prior SARS-CoV-2 infection (169/180) had neutralizing antibodies before the vaccination (Fig. 3A). Three weeks after the first vaccine dose, neutralizing titres against all four isolates were slightly increased (GMT of 24 for FIN-25, 32 for SR121, 24 for 85HEL (B.1.1.7), and 12 for HEL-12-102 (B.1.351)). Six weeks after the first dose of the vaccine (3 weeks after the second dose), neutralizing titres were increased to a GMT of 234 against FIN-25, 275 against SR121, 240 against 85HEL (B.1.1.7), and 102 against HEL-12-102 (B.1.351) (Fig. 3A, Table 1). Three weeks after the first dose 37%, 17%, 37%, and 85% of vaccinees had neutralization titre <20 against FIN-25, SR121, 85HEL (B.1.1.7), and HEL-12-102 (B.1.351) isolates, respectively. After the second vaccine dose, 100% of vaccinees had neutralizing antibodies against FIN-25, SR121 and 85HEL (B.1.1.7), whereas 92% of vaccinees had neutralizing antibodies against the HEL-12-102 (B.1.351) variant. GMTs against all four isolates in vaccinees exceeded the GMTs seen in convalescent-phase patient sera (Fig. 3A, Table 1).

Three weeks after the first vaccine dose, the GMT for HEL-12-102 (B.1.351) was 2-fold lower (p < 0.0001) compared to FIN-25 and 85HEL (B.1.1.7). After the second immunization, the GMT for HEL-12-102 (B.1.351) correlated relatively well and highly significantly (r = 0.8, p < 0.0001) (Fig. 4). MNT titres for FIN-25 and HEL-12-102 (B.1.351) correlated relatively well and highly significantly (r = 0.74, p < 0.0001), as did the two variants of concern, 85HEL (B.1.1.7) and HEL-12-102 (B.1.351) (r = 0.75, p < 0.0001).
**Fig. 3 Neutralization of B.1.1.7 and B.1.351 variants by BNT162b2 vaccinees’ sera and COVID-19 patient sera.** A Neutralization titres of initially seronegative vaccinees (n = 169) for D614G variants FIN-25 and SR121, and 85HEL (B.1.1.7) and HEL12-102 (B.1.351) variants before (0d), three (3wk), and six weeks (6wk) after the first dose of BNT162b2 vaccine and neutralization titres of convalescent sera of non-hospitalized patients (Conv, n = 50). Values above the groups indicate geometric mean titres (GMTs) and data are shown as geometric means and geometric SDs. Neutralization titres <20 were plotted as 10. B Neutralization titres 3 weeks (3wk) and six weeks (6wk) after the first dose of the vaccine. Statistical differences between the virus isolates were analyzed with Wilcoxon matched-pairs signed-rank test. Two-tailed p-values <0.05 were considered significant. Exact p-values were **=0.0201, ***=0.0015, ****<0.0001 for 3wk and 6wk. Values above the groups indicate geometric mean titres (GMTs) and data are shown as geometric means and geometric SDs. Neutralization titres <20 were plotted as 10.
To analyze the effect of age and gender on the antibody responses, the vaccinees were divided into age and gender groups, and the S1 IgG EIA and MNT results were compared between the groups (Fig. 5A and B). After the first vaccine dose, anti-S1 IgG antibody levels and neutralization titres were significantly lower in the older age group (55–65 years) compared to younger age groups (20–34 and 35–44 years) (Fig. 5A). However, after the second vaccine dose, the neutralization titres were similar between the age groups (GMT 257, 268, 200, and 206 in age groups of 20–34, 35–44, 45–54, and 55–65 years, respectively) (Fig. 5A). We also compared gender-related antibody responses even though male vaccinees were underrepresented, comprising only 17% (29/169) of the vaccinees. After the second dose, female vaccinees had slightly higher neutralization titres than males ($p = 0.0412$), although the anti-S1 IgG antibody levels remained at the same level (Fig. 5B).

**EIA values correlate with MNT titres.** Neutralization tests with live SARS-CoV-2 viruses are very time-consuming, and at the moment the assay requires BSL-3 laboratory conditions, whereas EIA and other similar colorimetric/fluorometric antibody assays are faster and user-friendly. To assess whether EIA values are associated with MNT titres, anti-S1 IgG and total anti-S1 Ig were compared to neutralization titres against FIN-25 (Fig. 6, Supplementary Fig. 3). Both anti-S1 IgG and total anti-S1 Ig EIA measurements correlated very well with MNT titres ($r > 0.9$, $p < 0.0001$) suggesting that EIA, especially IgG EIA, using spike protein as an antigen can be a useful method to determine COVID-19 immunity.

**Discussion**

The emergence of the COVID-19 pandemic in early 2020 prompted a rapid development of various types of vaccines such as mRNA encoding SARS-CoV-2 spike protein, viral vector-based (e.g. adenovirus), inactivated virus, virus-like particle, and recombinant protein vaccines. Once the European Union had made agreements with a number of vaccine producers, mass immunization was started in Finland at the end of December 2020, first with the mRNA-based Pfizer-BioNTech vaccine and somewhat later the Moderna mRNA and AstraZeneca adenovirus-based vaccines. Vaccination of health care professionals within a national vaccination programme in Finland enabled us to start, independent of pharmaceutical companies, a follow-up study of vaccine-induced immunity. In the present report, we show that two-dose vaccination with the BNT162b2 mRNA COVID-19 vaccine induces very high antibody levels against viral spike protein and high titres of neutralizing antibodies. The vaccine induced good cross-reactivity to D614G and B.1.1.7 variants in all vaccinees and, albeit reduced levels, detectable neutralizing antibodies to B.1.351 variant in 92% of the vaccinees.

EIA is a rapid and sensitive method to analyze immune responses against vaccine antigens or different viral proteins in response to infection. The method is easily quantitative and suitable for analyzing different immunoglobulin classes. In this study, we observed that practically all seronegative health care workers (20–65 years of age) responded to the first BNT162b2 vaccine dose and an increase in spike protein-specific antibody
responses in the IgG antibody class was detectable. The IgG antibody levels varied considerably and relatively few individuals showed increased antibody levels in the IgA and IgM antibody classes. The second vaccine dose, which was given according to the original vaccination protocol 3 weeks after the first vaccine dose, induced very high levels of spike protein-specific IgG antibodies, while IgA and IgM responses remained low. The vaccinees’ IgG antibody levels were on average higher than those seen in convalescent-phase sera of home-treated patients. Antibody responses have been found generally higher for COVID-19 patients with a more severe disease, however, as shown by this study also, the BNT162b2 vaccine appears to induce higher antibody responses against SARS-CoV-2 S1 protein and neutralization of FIN-25 by age and gender. A BNT162b2 vaccinated health care workers (initially seronegative, n = 169) were divided into four age groups. Age specific differences of anti-S1 IgG antibody levels and neutralization titres against FIN-25 virus isolate were analyzed. Sera was collected three weeks (3wk) and six weeks (6wk) after the first vaccine dose. Differences between age groups were tested with two-tailed Mann–Whitney U test. Two-tailed p-values < 0.05 were considered significant. Exact p-values were **=0.0078, ***=0.0007, and ****<0.0001 for 3wk EIA, **=0.0201 (age group 35–44 vs. 55–65), =0.0.231, and *=0.0041 for 6wk EIA, and *=0.0133 and ***=0.0005 for 3wk MNT. B Gender-specific differences in S1 specific IgG antibody responses and neutralization titres against FIN-25 were analyzed. Differences between age and gender groups were tested with two-tailed Mann–Whitney U test. Two-tailed p-values <0.05 were considered significant. Exact p-values were *=0.0412. The data in A and B are presented as geometric means and geometric SDs. Neutralization titres <20 were plotted as 10.

Fig. 5 Antibody responses against SARS-CoV-2 S1 protein and neutralization of FIN-25 by age and gender. A BNT162b2 vaccinated health care workers (initially seronegative, n = 169) were divided into four age groups. Age specific differences of anti-S1 IgG antibody levels and neutralization titres against FIN-25 virus isolate were analyzed. Sera was collected three weeks (3wk) and six weeks (6wk) after the first vaccine dose. Differences between age groups were tested with two-tailed Mann–Whitney U test. Two-tailed p-values < 0.05 were considered significant. Exact p-values were **=0.0078, ***=0.0007, and ****<0.0001 for 3wk EIA, **=0.0201 (age group 35–44 vs. 55–65), =0.0.231, and *=0.0041 for 6wk EIA, and *=0.0133 and ***=0.0005 for 3wk MNT. B Gender-specific differences in S1 specific IgG antibody responses and neutralization titres against FIN-25 were analyzed. Differences between age and gender groups were tested with two-tailed Mann–Whitney U test. Two-tailed p-values <0.05 were considered significant. Exact p-values were *=0.0412. The data in A and B are presented as geometric means and geometric SDs. Neutralization titres <20 were plotted as 10.
antibody levels than those measured in patients\textsuperscript{29,30}. Remarkably, the administration of two doses of the mRNA vaccine induced very high antibody responses in 100% of the vaccinees. The global circulation of SARS-CoV-2 and a huge number of infections worldwide have led to the emergence of hundreds of evolutionary lineages and variants of the virus (https://cov-lineages.org/global_report.html). The evolutionary speed of SARS-CoV-2 has been relatively slow, at least compared to influenza A viruses, presumably due to a virus-encoded enzyme with a proof-reading capability. Within the first 16 months of circulation, up to 30–35 mutations have been identified accumulating into the viral genome. Many of these mutations are silent or appear in places of the genome that are not critical for avoiding immunity induced by vaccination or natural infection. However, a number of variants have raised concern due to mutations accumulating particularly in the S-gene and causing changes in the immunodominant epitopes of the trimeric spike protein. Mapping the spike protein mutations on variants sequenced and used in this study revealed that they occur outside the globular head of the trimeric spike protein. The D614G and B.1.1.7 variant viruses were readily neutralized by the vaccinees’ sera, indicating that these mutations are unlikely to impair the neutralizing antibody capacity induced by vaccination or natural infection. However, it should be noted that the neutralizing titre of these sera was five-fold lower against the B.1.351 variant, which denotes that the amino acid changes accumulating in this variant are potentiating the escape of the virus from the humoral immune response. Despite this, more than 92% of the vaccinees showed measurable neutralizing antibody titres against the B.1.351 variant, suggesting that the spike protein encoded by Pfizer-BioNTech’s mRNA vaccine is similar enough to also mount an immune response against the B.1.351 variant.

The critical amino acid changes linked to escape from humoral immunity in the B.1.351 variant appear to be K417N, E484K, and N501Y\textsuperscript{30–32}. These amino acids are situated in the grooves within the receptor-binding site of the trimeric S protein complex. There is no three-dimensional structure presently available for the B.1.351 variant spike protein trimer, but because of its relatively radical amino acid substitutions, conformational changes in the spike structure may prove substantial. Interestingly, the B.1.351 and B.1.1.7 variants have deletions in the tips of the globular S1 domain (amino acids 243–245 and amino acids 69–70 and 244, respectively) which could contribute to the impaired recognition by neutralizing antibodies.

It is currently not known how high neutralizing antibody titres against a given virus variant are required for antibody-mediated protection against the COVID-19. However, the clinical efficacy data accumulating from COVID-19 vaccine studies strongly suggest that already one dose of the vaccine provides protection against severe COVID-19, even when neutralizing antibody levels cannot be detected in all vaccinees\textsuperscript{33,34}. This suggests that the first vaccine dose may prime the individual for rapid induction of protective immunity when contracting the virus in nature and avoiding severe COVID-19. According to previous data\textsuperscript{29,35–38}, we found that individuals with prior SARS-CoV-2 infection readily responded to the first vaccine dose with high antibody levels and neutralization titres.

Humoral immune response to vaccinations has been shown to decline with age\textsuperscript{39,40}. Consistently, we observed a trend of declining immune response to the COVID-19 mRNA vaccine by age. This trend was not very strong, presumably because the ages of our vaccinees ranged from 20 to 65 years, while age-dependent immunosenescence should be more pronounced in the age group >65 years\textsuperscript{39}. Another explanation might be that the BNT162b2 mRNA vaccine is exceptionally immunogenic and therefore, especially when given two doses, it enables practically all individuals regardless of gender and age, to develop high antibody levels and neutralization titres.

In summary, in the present study we show that the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine is highly immunogenic, and particularly after two vaccine doses, all vaccinees showed a very high humoral immune response to D614G variant viruses. Immunity to a recent B.1.1.7 variant was equally good as compared to the D614G variant, whereas vaccine and SARS-CoV-2 infection induced immunity against B.1.351 variant was reduced. Despite this, almost all vaccinees showed neutralizing antibodies against the B.1.351 variant, suggesting to provide at least some degree of protection against these variant viruses. In the future, it will be intriguing to study the development and persistence of cell-mediated immunity induced by COVID-19 vaccines. Promising data have been reported at least for the BNT162b2 vaccine which in preliminary studies has induced good cell-mediated immunity\textsuperscript{41,42}. As the use of other types of SARS-CoV-2 vaccines will be increased, it is the responsibility of the scientific community and public health professionals to systematically collect serum and cellular samples for comparative analyses of vaccine-induced immunity, cross-protection, and longevity of vaccine and natural infection-induced immunity.

As a whole, all vaccines that have currently obtained market authorization in the EU show excellent protective efficacy against severe COVID-19. Thus, it is very likely that immunogenicity results similar to those presented here will be applicable to them as well.
SARS-CoV-2 protein expression was done as described previously. Brie-
ly, Study participants (Helsinki, Finland) (Helsinki-Uusimaa health district ethical permission HUS/1238/2020) were recruited by coating 96-well microtitre plates (Nunc Maxisorp, Thermo Fisher Scientific) with BWA-MEM47 algorithm implemented in SAMTools version 1.848. Sequences of four SARS-CoV-2 isolates used in this study were deposited in GenBank: FIN-25 (GenBank MWJ17675), SR121 (GenBank MWJ17676), 85HEL (GenBank MWJ17677), and HEL-12-102 (GenBank MWJ17678).

**Microneutralization test.** Neutralizing antibodies were measured using a micro-
neutralization test (MNT). Serum samples were serially diluted two-fold, starting at 1:10 dilution in 2% FBS in DMEM and incubated with an equal volume of 50 TCID₅₀ of SARS-CoV-2 isolate in 96-well tissue culture plates (Sarstedt) for 1 h at 37 °C (final serum dilution 1:20). VeroE6-TMPRSS2-H10 cells were added (40,000 cells per well) and the plates were incubated at 37 °C, 5% CO₂, for 3 days. Cells were fixed with 4% formaldehyde and stained with crystal violet. MNT titers were calculated as the reciprocal dilution resulting in 50% inhibition of cell death. MNT assays were done at the BSL-3 laboratory conditions.

**Statistical analysis.** Data were analyzed in Excel 2016 (Microsoft). Geometric means with geometric standard deviations (SD) were calculated with GraphPad Prism 8 software. Statistical significance of differences between variants was ana-
lyzed with Wilcoxon matched-pairs signed-rank test, and two-tailed p-values < 0.05 were considered significant. Differences between age and gender groups were tested with two-tailed Mann–Whitney U test. All serum samples were analyzed in duplicates.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

Data are available upon request from the corresponding authors. Source data are provided with this paper. The SARS-CoV-2 sequence data generated in this study have been deposited in the GenBank database under accession codes MWJ17675, MWJ17676, MWJ17677 and MWJ17678. received: 18 March 2021; accepted: 11 June 2021; published online: 28 June 2021.

**References**

1. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534 (2020).
2. Dong, Y. et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct. Target. Ther. 5, 237 (2020).
3. Okba, N. M. A. et al. Severe acute respiratory syndrome coronavirus 2—specific antibody responses in coronavirus disease patients. Emerg. Infect. Dis. 26, 1478–1488 (2020).
4. Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat. Med.* 26, 1033–1036 (2020).

5. Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* 370, 1227–1230 (2020).

6. Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science* 369, 818–823 (2020).

7. Alsoussi, W. B. et al. A potently neutralizing antibody protects mice against SARS-CoV-2 infection. *J. Infect.* 62, 949–9469 (2020).

8. Hanrath, A. T., Payne, R. A. I. & Duncan, C. J. A. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. *J. Infect.* 82, e29–e30 (2020).

9. Hall, V. J. et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet* 397, 1459–1469 (2020).

10. Chodick, G. et al. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine. *Vaccine.*

11. Pradenas, E. et al. Stable neutralizing antibody levels 6 months after mild and asymptomatic COVID-19 infection. *ImmunoL* 205, 915–922 (2020).

12. Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. *Nature* 592, 823–825 (2021).

13. Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat. Med.* 26, 1033–1036 (2020).

14. Saadat, S. et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. *JAMA* 325, 1467–1469 (2021).

15. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med.* 383, 2603–2615 (2020).

16. Capetti, A. F. et al. Impressive boosting of anti-S/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 vaccine. *Clin. Infect. Dis.* ciab214 (2021).

17. Chen, W. H. et al. Vaccination in the elderly: an immunological perspective. *Trends Immunol.* 30, 351–359 (2019).

18. Prendecki, M. et al. Effect of previous SARS-CoV-2 infection on humoral and proliferative SARS-CoV-2 infection. *BIOEN* 307, e1469 (2021).

19. Jalkanen, P. et al. A combination of N and S antigens with IgA and IgG measurement strengthens the accuracy of SARS-CoV-2 serodiagnoses. *J. Infect.* 62, jiaa222 (2021).

20. Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South Africa’s single-dose SARS-CoV-2 variant of concern. *Virology.*

21. Deng, W. et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science* 369, 818–823 (2020).

22. Alsoussi, W. B. et al. A potently neutralizing antibody protects mice against SARS-CoV-2 infection. *J. Infect.* 62, 949–9469 (2020).

23. Chodick, G. et al. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. *JAMA Netw. Open.* 4, e2115985 (2021).

24. Pradenas, E. et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. *Med.* 2, 313–320 (2021).

25. Public Health England. *Investigation of SARS-CoV-2 Variants of Concern in England.*

26. Lynch, K. L. et al. Magnitude and kinetics of anti-severe acute respiratory syndrome Coronavirus 2 antibody responses and their relationship to disease severity. *Clin. Infect. Dis.* 72, 301–308 (2021).

27. Grossberg, A. N. et al. A multiplex chemiluminescent immunoassay for detection of antibodies against severe acute respiratory syndrome Coronavirus 2 antibody responses and their relationship to disease severity. *Clin. Infect. Dis.* 72, 301–308 (2021).

28. Corbey, S. et al. Escape of SARS-CoV-2 S protein neutralization by convalescent plasma. *Nature* 593, 142–146 (2021).

29. Virtanen, J. et al. Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7 and B.1.351 Isolates in Microneutralization Assays. *Viruses* 13, 996 (2021).

30. De Wit, C. S., Inglesby, T. V., Osterholm, M. T., Perl, T. R., Stephens, D. B. & Judson, F. S. The Antibody Response to SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-blind, Randomised Controlled Trial. *Lancet* 396, 467–478 (2020).

31. SARS-CoV-2 variant B.1.351 from South Africa: preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* 396, 467–478 (2020).

32. Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. *N. Engl. J. Med.* 383, 2427–2438 (2020).

33. Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. *N. Engl. J. Med.* 383, 2439–2450 (2020).

34. Public Health England. *Investigation of SARS-CoV-2 Variants of Concern in England.*

35. Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. *N. Engl. J. Med.* 384, 1372–1374 (2021).

36. Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N. Engl. J. Med.* 384, 1412–1423 (2021).

37. Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and selected B.1.351 variants. *Nat. Commun.* 1466 (2021).

38. Grossberg, A. et al. The Antibody Response to SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-blind, Randomised Controlled Trial. *Lancet* 396, 467–478 (2020).

39. Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South Africa’s single-dose SARS-CoV-2 variant of concern. *Virology.*

40. Li, H. et al. Aiding sequence recovery: three sequences and assembly contigs with BWA-MEM. Preprint at arXiv:1303.3997 (2013).

41. Li, H. et al. The sequence alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079 (2009).

42. Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* 181, 281–292.e6 (2020).

Acknowledgements

We thank Soili Jussila for cell maintenance, Mikael Ritvos for assistance in protein production, and Anne Suominen, Anne-Mari Penniniemi, and Simo Miettinen for technical assistance. J.I. was funded by Jane and Aatos Erkko Foundation (grant numbers 3067–84b53 and 5360-cc2fc), the Academy of Finland (AoF; grant numbers 336410 and 337530) and Sigrid Jusélius Foundation. J.H. was funded by AoF (grant number 308613) and K.A.C. was funded by AoF (grant numbers 336439 and 335527), the Finnish Medical Foundation, and private donors through UH. O.V., T.S., and S.K. were funded by Jane and Aatos Erkko Foundation, AoF (grant numbers 336490 to O.V.) and Helsinki University Hospital Funds (TYH2018322). P.A.T., L.I., and J.L. were funded by The Turku University Hospital Research Foundation.

Author contributions

P.J., L.K., J.L., A.K. and I.J. designed the experiments; P.J., P.K., M.H., S.M., R.L. and L.K. did microneutralization tests and analyzed the data; H.K.H., S.H.P., P.A.T., L.L., A.N., T.M., H.V., L.I., J.L. and A.K. recruited vaccinees and patients and collected their sera and data; A.P., R.N., P.J. and O.R. produced antigens for EIA; P.O., S.K., H.I. and O.V. isolated and characterized virus strains; J.H. produced VeroE6-TMPRSS2-H10 cell line; T.S. did sequencing and T.S., J.H. and P.K. analyzed sequences and structures; P.I. analyzed all data sets; P.J., L.K., A.K. and I.J. wrote the manuscript and all co-authors contributed to the edition of the text.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-24285-4.

Correspondence and requests for materials should be addressed to P.J. or I.J.

Peer review information *Nature Communications* thanks Peter Kelleher and the other anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
